Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
Background: Numerous PSMA-based tracers are used for diagnostic prostate cancer imaging, but comprehensive comparisons between multiple ligands are lacking. This study aimed to compare physiological skeletal uptake and tracer uptake in commonly recommended PSMA reference regions across three differe...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/17/11/1458 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846152731411087360 |
|---|---|
| author | Zsófia Sára Mikó László Varga István Farkas Gyula Tóth Kristóf Apró Barnabás Márk Révész Gábor Sipka Péter Gergő Tompa Annamária Bakos Tamás Czékus Mátyás Bukva László Pávics Linda Varga Anikó Maráz Zsuzsanna Besenyi |
| author_facet | Zsófia Sára Mikó László Varga István Farkas Gyula Tóth Kristóf Apró Barnabás Márk Révész Gábor Sipka Péter Gergő Tompa Annamária Bakos Tamás Czékus Mátyás Bukva László Pávics Linda Varga Anikó Maráz Zsuzsanna Besenyi |
| author_sort | Zsófia Sára Mikó |
| collection | DOAJ |
| description | Background: Numerous PSMA-based tracers are used for diagnostic prostate cancer imaging, but comprehensive comparisons between multiple ligands are lacking. This study aimed to compare physiological skeletal uptake and tracer uptake in commonly recommended PSMA reference regions across three different PSMA ligands in prostate cancer patients. Methods: A total of 281 prostate cancer patients were included. Using PET and SPECT imaging, target volumes of interest were defined via a semiautomatic method, and standardized uptake values (SUV) were calculated for the skeletal system and reference regions (liver, spleen, parotid gland, and blood pool). Results: Significant differences in SUV uptake were observed, with [<sup>18</sup>F]F-PSMA-1007 showing higher SUV values in the skeletal system. The parotid gland displayed the highest variability in uptake, while the blood pool and liver exhibited more homogeneous uptake across patients. Conclusions: While radioligands behave similarly in bone regions, there are notable differences in SUV patterns, particularly for PSMA-1007, which showed higher bone uptake. Parotid gland uptake variability suggests a reconsideration of its suitability as a reference region, while the liver, spleen, and blood pool showed more consistent uptake. During comparison, the technetium-labeled SPECT ligand proved as similarly effective as the two PET ligands for diagnostic imaging. |
| format | Article |
| id | doaj-art-a7109de47e14450fb28a94a221965ba6 |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-a7109de47e14450fb28a94a221965ba62024-11-26T18:17:14ZengMDPI AGPharmaceuticals1424-82472024-10-011711145810.3390/ph17111458Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal SystemZsófia Sára Mikó0László Varga1István Farkas2Gyula Tóth3Kristóf Apró4Barnabás Márk Révész5Gábor Sipka6Péter Gergő Tompa7Annamária Bakos8Tamás Czékus9Mátyás Bukva10László Pávics11Linda Varga12Anikó Maráz13Zsuzsanna Besenyi14Department of Nuclear Medicine, University of Szeged, 6720 Szeged, HungaryDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, HungaryDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, HungaryPozitron Diagnosztika Ltd., 1117 Budapest, HungaryDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, HungaryDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, HungaryDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, HungaryDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, HungaryDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, HungaryDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, HungaryDepartment of Immunology, University of Szeged, 6720 Szeged, HungaryDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, HungaryDepartment of Oncotherapy, University of Szeged, 6720 Szeged, HungaryDepartment of Oncotherapy, University of Szeged, 6720 Szeged, HungaryDepartment of Nuclear Medicine, University of Szeged, 6720 Szeged, HungaryBackground: Numerous PSMA-based tracers are used for diagnostic prostate cancer imaging, but comprehensive comparisons between multiple ligands are lacking. This study aimed to compare physiological skeletal uptake and tracer uptake in commonly recommended PSMA reference regions across three different PSMA ligands in prostate cancer patients. Methods: A total of 281 prostate cancer patients were included. Using PET and SPECT imaging, target volumes of interest were defined via a semiautomatic method, and standardized uptake values (SUV) were calculated for the skeletal system and reference regions (liver, spleen, parotid gland, and blood pool). Results: Significant differences in SUV uptake were observed, with [<sup>18</sup>F]F-PSMA-1007 showing higher SUV values in the skeletal system. The parotid gland displayed the highest variability in uptake, while the blood pool and liver exhibited more homogeneous uptake across patients. Conclusions: While radioligands behave similarly in bone regions, there are notable differences in SUV patterns, particularly for PSMA-1007, which showed higher bone uptake. Parotid gland uptake variability suggests a reconsideration of its suitability as a reference region, while the liver, spleen, and blood pool showed more consistent uptake. During comparison, the technetium-labeled SPECT ligand proved as similarly effective as the two PET ligands for diagnostic imaging.https://www.mdpi.com/1424-8247/17/11/1458PSMAradiopharmaceuticalSPECTPETUBU (unknown bone uptake)PSMA-1007 |
| spellingShingle | Zsófia Sára Mikó László Varga István Farkas Gyula Tóth Kristóf Apró Barnabás Márk Révész Gábor Sipka Péter Gergő Tompa Annamária Bakos Tamás Czékus Mátyás Bukva László Pávics Linda Varga Anikó Maráz Zsuzsanna Besenyi Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System Pharmaceuticals PSMA radiopharmaceutical SPECT PET UBU (unknown bone uptake) PSMA-1007 |
| title | Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System |
| title_full | Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System |
| title_fullStr | Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System |
| title_full_unstemmed | Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System |
| title_short | Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System |
| title_sort | different psma radiopharmaceuticals a comparative study of sup 18 sup f f psma 1007 sup 18 sup f f jk psma 7 and sup 99m sup tc tc psma i s in the skeletal system |
| topic | PSMA radiopharmaceutical SPECT PET UBU (unknown bone uptake) PSMA-1007 |
| url | https://www.mdpi.com/1424-8247/17/11/1458 |
| work_keys_str_mv | AT zsofiasaramiko differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT laszlovarga differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT istvanfarkas differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT gyulatoth differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT kristofapro differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT barnabasmarkrevesz differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT gaborsipka differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT petergergotompa differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT annamariabakos differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT tamasczekus differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT matyasbukva differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT laszlopavics differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT lindavarga differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT anikomaraz differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem AT zsuzsannabesenyi differentpsmaradiopharmaceuticalsacomparativestudyofsup18supffpsma1007sup18supffjkpsma7andsup99msuptctcpsmaisintheskeletalsystem |